South Korea
· Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 180.76 billion. The enterprise value is 126.95 billion.
| Market Cap | 180.76B |
| Enterprise Value | 126.95B |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Whan In Pharm has 15.27 million shares outstanding.
| Current Share Class | 15.27M |
| Shares Outstanding | 15.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.36% |
| Owned by Institutions (%) | 15.94% |
| Float | 10.94M |
Valuation Ratios
The trailing PE ratio is 9.30 and the forward PE ratio is 7.52.
| PE Ratio | 9.30 |
| Forward PE | 7.52 |
| PS Ratio | 0.70 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | 60.33 |
| P/OCF Ratio | 8.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.55, with an EV/FCF ratio of 42.37.
| EV / Earnings | 6.53 |
| EV / Sales | 0.49 |
| EV / EBITDA | 4.55 |
| EV / EBIT | 6.76 |
| EV / FCF | 42.37 |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.52 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.26 |
| Interest Coverage | 753.41 |
Financial Efficiency
Return on equity (ROE) is 5.26% and return on invested capital (ROIC) is 3.12%.
| Return on Equity (ROE) | 5.26% |
| Return on Assets (ROA) | 2.73% |
| Return on Invested Capital (ROIC) | 3.12% |
| Return on Capital Employed (ROCE) | 4.82% |
| Revenue Per Employee | 422.56M |
| Profits Per Employee | 31.80M |
| Employee Count | 611 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.42 |
Taxes
In the past 12 months, Whan In Pharm has paid 2.09 billion in taxes.
| Income Tax | 2.09B |
| Effective Tax Rate | 9.70% |
Stock Price Statistics
The stock price has decreased by -20.13% in the last 52 weeks. The beta is 0.31, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -20.13% |
| 50-Day Moving Average | 11,669.00 |
| 200-Day Moving Average | 12,126.45 |
| Relative Strength Index (RSI) | 60.17 |
| Average Volume (20 Days) | 20,584 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 258.19 billion and earned 19.43 billion in profits. Earnings per share was 1,272.45.
| Revenue | 258.19B |
| Gross Profit | 89.70B |
| Operating Income | 18.46B |
| Pretax Income | 21.52B |
| Net Income | 19.43B |
| EBITDA | 27.56B |
| EBIT | 18.46B |
| Earnings Per Share (EPS) | 1,272.45 |
Balance Sheet
The company has 54.60 billion in cash and 788.15 million in debt, giving a net cash position of 53.81 billion or 3,524.79 per share.
| Cash & Cash Equivalents | 54.60B |
| Total Debt | 788.15M |
| Net Cash | 53.81B |
| Net Cash Per Share | 3,524.79 |
| Equity (Book Value) | 375.99B |
| Book Value Per Share | 24,627.32 |
| Working Capital | 161.02B |
Cash Flow
In the last 12 months, operating cash flow was 21.09 billion and capital expenditures -18.09 billion, giving a free cash flow of 3.00 billion.
| Operating Cash Flow | 21.09B |
| Capital Expenditures | -18.09B |
| Free Cash Flow | 3.00B |
| FCF Per Share | 196.27 |
Margins
Gross margin is 34.74%, with operating and profit margins of 7.15% and 7.53%.
| Gross Margin | 34.74% |
| Operating Margin | 7.15% |
| Pretax Margin | 8.33% |
| Profit Margin | 7.53% |
| EBITDA Margin | 10.68% |
| EBIT Margin | 7.15% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.54%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.57% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.51% |
| Earnings Yield | 10.75% |
| FCF Yield | 1.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 4.65 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.65 |
| Piotroski F-Score | 6 |